Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Heart failure is a life‐threatening disease and addressing it should be considered a global
health priority. At present, approximately 26 million people worldwide are living with heart …

Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded
as a benign condition. Recently, it has been shown that TTS may be associated with severe …

Background Inflammation in the tumour microenvironment mediated by interleukin 1β is
hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did …

The endothelium can evoke relaxations (dilatations) of the underlying vascular smooth
muscle, by releasing vasodilator substances. The best characterized endothelium‐derived …

Background— Prognosis of ischemic cardiomyopathy still remains poor because of the lack
of effective treatments. To develop a noninvasive therapy for the disorder, we examined the …

The endothelium plays an important role in maintaining vascular homeostasis by synthesizing
and releasing several endothelium-derived relaxing factors, such as prostacyclin, nitric …

Endothelium-dependent relaxations are achieved by a combination of endothelium-derived
prostacyclin (PGI 2), nitric oxide (NO), and endothelium-derived hyperpolarizing factor (…

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is …

The endothelium synthesizes and releases several vasodilating factors, including nitric oxide,
endothelium-derived hyperpolarizing factor, and prostacyclin. Under certain conditions, it …